Interv Akut Kardiol. 2015;14(1):22-25

Cardiomarkers in diagnostics of the heart failure

Radek Pudil
1 . interní kardioangiologická klinika LF UK a FN Hradec Králové

The article presents an overview of the current possibilities of the clinical use of cardiac markers in the diagnostics of heart failure. It

focuses primarily on natriuretic peptides, and it provides a basic knowledge of their origin and effect on the cardiovascular system. It

brings information about a preanalytical issue. The information about new potentially interesting markers (mid-regional pro-ANP and

mid-regional pro-adrenomedullin) is included.

Keywords: heart failure, natriuretic peptides, mid-regional pro-ANP, mid-regional pro-adrenomedullin

Published: April 20, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pudil R. Cardiomarkers in diagnostics of the heart failure. Interv Akut Kardiol. 2015;14(1):22-25.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Maisel A, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002; 347: 161-167. Go to original source... Go to PubMed...
    2. Hammerer-Lercher A, Halfinger B, Sarg B, et al. Analysis of circulating forms of proBNP and NT-proBNP in patients with severe heart failure. Clin Chem 2008; 54: 858-865. Go to original source... Go to PubMed...
    3. Christ M, Thuerlimann A, Laule K, et al. Long-term prognostic value of B-type natriuretic peptide in cardiac and non-cardiac causes of acute dyspnoea. Eur J Clin Invest 2007; 37: 834-841. Go to original source... Go to PubMed...
    4. Kucher N, Printzen G, Doernhoefer T, Windecker S, Meier B, Hess OM. Low NT-proBNP levels predict benign clinical outcome in acute pulmonary embolism. Circulation 2003; 107: 1576-1578. Go to original source... Go to PubMed...
    5. Waldo SW, Beede J, Isakson S, et al. Pro-B-type natriuretic peptide levels in acute decompensated heart failure. J Am Coll Cardiol 2008; 51: 1874-1882. Go to original source... Go to PubMed...
    6. Seferian KR, Tamm NN, Semenov AG, et al. The brain natriuretic peptide (BNP) precursor is the major immunoreactive form of BNP in patients with heart failure. Clin Chem 2007; 53: 866-873. Go to original source... Go to PubMed...
    7. Semenov AG, Tamm NN, Seferian KR, et al. Processing of pro-B-type natriuretic peptide: furin and corin as candidate convertases. Clin Chem 2010; 56: 1166-1176. Go to original source... Go to PubMed...
    8. Palmer CS, Yandle TG, Nicholls G, et al. Regional clearance of NT-proBNP from human plasma. Eur J Heart Fail 2009; 11: 832-839. Go to original source... Go to PubMed...
    9. Kimmenade RRJ, Januzzi JL, Bakker JA, et al. Renal clearance of BNP and NT- proBNP-a mechanistic study in hypertensive patients. J Am Coll Cardiol 2009; 53: 884-890. Go to original source...
    10. McMurray J, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 Eur Heart J 2012; 33(14): 1787-1847. Go to original source... Go to PubMed...
    11. Spinar J, Vitovec J, Hradec J, et al. Doporučený postup České kardiologické společnosti pro diagnostiku a léčbu chronického srdečního selhání, 2011. Cor et Vasa 2012; 54: e113-e134. Go to original source...
    12. Schneider HG, Lam L, Lokuge A, et al. B-type natriuretic peptide testing, clinical outcomes, and health services use in emergency department patients with dyspnea: a randomized trial. Ann Intern Med 2009; 150: 365-371. Go to original source... Go to PubMed...
    13. Rutten JH, Steyerberg EW, Boomsma F, et al. NT-proBNP testing in the emergency department: beneficial effects on hospitalization, costs and outcome. Am Heart J. 2008; 156: 71-77. Go to original source... Go to PubMed...
    14. N?rgaard BL, Terkelsen CJ, Riiskjaer M, Holmvang L, Grip L, Heickendorff L, Thygesen K. Risk prediction in acute coronary syndrome from serial in-hospital measurements of N-terminal pro-B-type natriuretic peptide. Acute Card Care 2008; 10: 159-166. Go to original source... Go to PubMed...
    15. Mayr A, Mair J, Schocke M, et al. Predictive value of NT-proBNP after acute myocardial infarction: relation with acute and chronic infarct size and myocardial function. Int J Cardiol 2009. doi: 10.1016/j.ijcard.2009.09.537. Go to original source... Go to PubMed...
    16. Lega JC, Lacasse Y, Lakhal L, Provencher S. Natriuretic peptides and troponins in pulmonary embolism: a meta-analysis. Thorax 2009; 64: 869-875. Go to original source... Go to PubMed...
    17. Mair J. Biochemistry of B-type natriuretic peptide - where are we now? Clin Chem Lab Med 2008; 46: 1507-1514. Go to original source... Go to PubMed...
    18. Siriwardena M, Kleffmann T, Ruygrok P, et al. B-type natriuretic peptide signal peptide circulates in human blood - evaluation as a potential biomarker of cardiac ischemia. Circulation 2010; 122: 255-264. Go to original source... Go to PubMed...
    19. Apple FS, Wu AH, Jaffe AS, et al. National Academy of Clinical Biochemistry; IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine. National academy of biochemistry and IFCC committee for standardization of markers of cardiac damage laboratory medicine practice guidelines: analytical issues for biomarkers of heart failure. Circulation 2007; 116: e95-e98. Go to original source... Go to PubMed...
    20. Apple FS, Panteghini M, Ravkilde J, et al. Committee on Standardization of Markers of Cardiac Damage of the IFCC. Quality specifications for B-type natriuretic peptide assays. Clin Chem 2005; 51: 486-493. Go to original source... Go to PubMed...
    21. Di Serio F, Ruggieri V, Varraso L, De Sario R, Mastrorilli A, Panisini N. Analytical evaluation of the Dade Behring Dimension RxL automated N-terminal proBNP (NT-proBNP) method and comparison with the Roche Elecsys 2010. Clin Chem Lab Med 2005; 43: 1263-1273. Go to original source... Go to PubMed...
    22. Pereire M, Azevedo A, Severo M, Barros H. Long-term stability of endogenous B-type natriuretic peptide after storage at -20 degrees C or -80 degrees C. Clin Chem Lab Med 2008; 46: 1171-1174. Go to original source... Go to PubMed...
    23. Prontera C, Zucchelli GC, Vittorini S, Storti S, Emdin M, Clerico A. Comparison between analytical performances of polyclonal and monoclonal electrochemiluminescence immunoassays for NT-proBNP. Clin Chim Acta 2009;400:70-73. Go to original source... Go to PubMed...
    24. Pfisterer M, Buser P, Rickli H et al.TIME-CHF Investigators. JAMA 2009; 301: 383-392. Go to original source... Go to PubMed...
    25. Porapakkham P, Zimmet H, Billah B, Krum H. B-type natriuretic peptide-guided heart failure therapy: a meta-analysis. Arch Intern Med 2010; 170: 507-514. Go to original source... Go to PubMed...
    26. Lainchbury JG, Troughton RW, Strangman KM, et al. N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial. J Am Coll Cardiol 2009; 55: 53-60. Go to original source... Go to PubMed...
    27. Berger R, Moertl D, Peter S, et al. N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure a 3-arm, prospective, randomized pilot study. J Am Coll Cardiol 2010; 55: 645-653. Go to original source... Go to PubMed...
    28. Thygesen K, Mair J, Mueller C, et al. Recommendations for the use of natriuretic peptides in acute cardiac care: A position statement from the Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care. Eur Heart J 2012; 33(16): 2001-2006. Go to original source... Go to PubMed...
    29. Goetze JP. B-type natriuretic peptide: from posttranslational processing ti clinical management. Clin Chem 2012; 58(1): 83-91. Go to original source... Go to PubMed...
    30. Maisel A, Mueller C, Nowak R, et al. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol. 2010; 55(19): 2062-2076. Go to original source... Go to PubMed...
    31. Klip IT, Voors AA, Anker SD, et al. Prognostic value of mid-regional pro-adrenomedullin in patients with heart failure after an acute myocardial infarction. Heart. 2011; 97(11): 892-898. Go to original source... Go to PubMed...
    32. Potocki M, Ziller R, Mueller C. Mid-regional pro-adrenomedullin in acute heart failure: a better biomarker or just another biomarker? Curr Heart Fail Rep. 2012; 9(3): 244-251. Go to original source... Go to PubMed...

    Return to the content


    Interventional Cardiology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.